Voices
Daisuke Kotani
Daisuke Kotani/X

Daisuke Kotani: ESMO-ESTRO Guidelines on Combining Radiotherapy with ICIs, VEGFi, and TKIs

Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X about a recent article by Wim Van Aken et al., published in ScienceDirect:

“ESMO-ESTRO consensus on the safety of combining radiotherapy with ICIs, VEGFi, or multi-TKIs

In GI field (thorax, abdomen, or pelvis)

  • PD-(L)1: minor/no adaptation
  • CTLA-4: major adaptations with high-dose RT
  • VEGFi: major adaptations
  • TKI: major adaptations.”

Daisuke Kotani

Title: ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

Authors: Wim Van Aken, B. Devnani, A. Prelaj, L. Castelo-Branco, C.A.M. Marijnen, D. Martins-Branco, M.A. Gambacorta, A. Lamarca, K. Harrington, G. Minniti, M. Hecht, D. Papamichael, M. Krause, R. Cathomas, K. Lindberg, S.M. O’Cathail, U. Nestle, J. Barriuso, S. Nowicki, C. Rödel, A.K. Gandhi

Read The Full Article in ScienceDirect.

Daisuke Kotani: ESMO-ESTRO Guidelines on Combining Radiotherapy with ICIs, VEGFi, and TKIs

More posts featuring Daisuke Kotani.

A Prelaj A. Lamarca A.K. Gandhi B. Devnani C. Rödel C.A.M. Marijnen cancer D. Martins Branco D. Papamichael Daisuke Kotani ESMO ESTRO G. Minniti J. Barriuso K. Harrington K. Lindberg L. Castelo-Branco M. Hecht M. Krause M.A. Gambacorta OncoDaily Oncology R. Cathomas S. Nowicki S.M. O’Cathail ScienceDirect U. Nestle Wim Van Aken